What is the minimum recommended initial workup for newly diagnosed AF?

Obtain a transthoracic echocardiogram, CBC, metabolic panel, and thyroid function testing. Avoid routine ischemia, ACS, or pulmonary embolism testing unless symptoms or signs suggest those disorders.

When is immediate cardioversion indicated in AF?

Immediate direct-current cardioversion is indicated for hemodynamic compromise. Most stable patients do not require immediate cardioversion and can first receive rate control and individualized rhythm-control assessment.

When should a DOAC not be used for AF stroke prevention?

Avoid DOACs with mechanical heart valves and with rheumatic or moderate-to-severe mitral stenosis; use warfarin in these settings.

When should catheter ablation be discussed in AF with HFrEF?

Discuss ablation in appropriate patients with AF and HFrEF receiving guideline-directed medical therapy when procedural benefit is reasonably expected; it can improve symptoms, ventricular function, quality of life, and cardiovascular outcomes.

Atrial Fibrillation

A practical framework for confirming atrial fibrillation, defining acute stability, completing the initial evaluation, preventing thromboembolism, selecting rate or rhythm control, and identifying patients who benefit from catheter ablation or focused heart-failure management.

Diagnosis

Confirm AF and complete the first evaluation

Establish the rhythm diagnosis, identify instability, and define factors that change immediate treatment.

AF requires ECG documentation. Typical findings are irregularly irregular R-R intervals when atrioventricular conduction is intact, absent distinct repeating P waves, and irregular fibrillatory atrial activity.BMJ+1BMJEstablished atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice BMJNew-onset atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice US Device-detected atrial high-rate episodes require visual review to distinguish AF from other atrial tachyarrhythmias, artifact, or oversensing.BMJBMJEstablished atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice

For newly diagnosed AF, order transthoracic echocardiography, CBC, metabolic panel, and thyroid function testing. Echocardiography informs chamber and valve assessment, ventricular function, and downstream antiarrhythmic or ablation selection; laboratory testing identifies renal, hepatic, hematologic, and thyroid factors that alter anticoagulant and antiarrhythmic choices.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

Do not use AF alone as an indication for routine protocolized ischemia, acute coronary syndrome, or pulmonary embolism testing; investigate when symptoms, signs, or clinical context support those diagnoses.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
If onset timing is uncertain and cardioversion is contemplated in a hemodynamically stable patient, transesophageal echocardiography is used to exclude left atrial thrombus before cardioversion.BMJBMJNew-onset atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice US

Initial evaluation priorities in newly diagnosed atrial fibrillation.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Question	Action	Clinical consequence
Is AF documented?	Obtain and interpret ECG for AF features.BMJ+1BMJEstablished atrial fibrillation - Symptoms, diagnosis and treatment \| BMJ Best Practice BMJNew-onset atrial fibrillation - Symptoms, diagnosis and treatment \| BMJ Best Practice US	Confirms diagnosis before disease-specific treatment.
Is the patient unstable?	Assess blood pressure, ischemia, pulmonary edema, shock, and altered perfusion.	Hemodynamic compromise prompts immediate direct-current cardioversion.BMJBMJNew-onset atrial fibrillation - Symptoms, diagnosis and treatment \| BMJ Best Practice US
Is there structural disease or ventricular dysfunction?	Order transthoracic echocardiography.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	Influences rate-control drug safety, rhythm strategy, and ablation candidacy.
Are reversible or treatment-modifying factors present?	Obtain CBC, metabolic panel, and thyroid function testing.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	Guides anticoagulant dosing, bleeding assessment, and treatment of associated conditions.

Acute Care

Stabilize first, then select rate or rhythm control

Urgency is determined by hemodynamics, not simply by a rapid ventricular response.

Most patients with new-onset or acute AF do not require immediate cardioversion. In hemodynamically stable AF, initial ventricular rate control is commonly used while clinicians address triggers, assess thromboembolic risk, and determine whether rhythm control is appropriate.BMJBMJNew-onset atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice US

For hemodynamically stable AF with rapid ventricular response and ejection fraction >40%, beta-blockers or nondihydropyridine calcium channel blockers such as diltiazem or verapamil are recommended for acute rate control. Do not administer intravenous nondihydropyridine calcium channel blockers in known moderate or severe LV systolic dysfunction, with or without decompensated heart failure.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

Use direct-current cardioversion immediately for hemodynamic compromise.BMJBMJNew-onset atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice US
For stable AF, discuss rate versus rhythm control in the context of symptoms, clinical presentation, comorbidity burden, medication profile, and patient preferences.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
A lenient resting rate target below 110 beats/min produced similar cardiovascular outcomes and symptoms to a strict target below 80 beats/min in hemodynamically stable AF in the cited evidence base.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

High-value acute management distinctions.BMJ+1BMJNew-onset atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice US jacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Clinical state	Preferred next step	Avoid or reassess
Hemodynamic compromise	Immediate direct-current cardioversion.BMJBMJNew-onset atrial fibrillation - Symptoms, diagnosis and treatment \| BMJ Best Practice US	Do not delay stabilization for routine longitudinal testing.
Stable AF with rapid ventricular response and EF >40%	Beta-blocker or diltiazem/verapamil for acute rate control.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	Reassess for rhythm-control indications after stabilization.
Rapid ventricular response with moderate/severe LV systolic dysfunction	Avoid intravenous diltiazem or verapamil.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	Do not assume nondihydropyridine calcium channel blockers are safe in HFrEF.
Uncertain duration before planned cardioversion	Use transesophageal echocardiography to exclude left atrial thrombus.BMJBMJNew-onset atrial fibrillation - Symptoms, diagnosis and treatment \| BMJ Best Practice US	Do not proceed as though onset is known.

Thromboembolism

Base anticoagulation on annual thromboembolic risk

AF pattern does not remove the need for risk-based stroke prevention.

Assess annual thromboembolic risk with a validated clinical score such as CHA2DS2-VASc; ATRIA and GARFIELD-AF are alternatives referenced in current U.S. performance measures.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Anticoagulation is recommended for estimated annual thromboembolic risk of at least 2%, illustrated by CHA2DS2-VASc ≥2 in men or ≥3 in women. Anticoagulation is reasonable at estimated risk of 1% to <2% per year.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

For anticoagulation candidates without moderate-to-severe rheumatic mitral stenosis or a mechanical heart valve, DOACs are recommended over warfarin to reduce mortality, stroke, systemic embolism, and intracranial hemorrhage.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Aspirin alone, or aspirin plus clopidogrel as an alternative to anticoagulation, is not recommended for AF stroke prevention in patients who are anticoagulation candidates.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

Use warfarin rather than a DOAC for AF with rheumatic mitral stenosis or mitral stenosis of moderate or greater severity, and avoid DOACs with mechanical heart valves.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
In end-stage CKD with creatinine clearance <15 mL/min or dialysis, the cited U.S. measure identifies warfarin or an evidence-based dose of apixaban as options that may be reasonable; dabigatran and edoxaban are inappropriate in this setting.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Reassess anticoagulant dose and interacting drugs as renal function, age, body weight, and medication lists change. Real-world data show frequent reduced-dose prescribing and possible undertreatment when label-based criteria are not met.NatureNatureStarting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation | Scientific Reports

Anticoagulation decisions in atrial fibrillation.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Situation	Action	Key limitation or exception
Estimated thromboembolic risk ≥2%/year	Prescribe anticoagulation unless contraindicated.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	CHA2DS2-VASc ≥2 in men or ≥3 in women is an example threshold.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Eligible for anticoagulation without significant mitral stenosis or mechanical valve	Prefer a DOAC over warfarin.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	Use drug-specific FDA labeling for dose selection.
Moderate/severe mitral stenosis or mechanical valve	Use warfarin rather than a DOAC.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	DOAC use is inappropriate in these populations.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
AF with PCI and an anticoagulation indication	Use a DOAC plus P2Y12 inhibitor and discontinue aspirin early, generally within 1 to 4 weeks.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	Longer triple therapy may be considered when perceived stent-thrombosis risk is high.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
AF with stable coronary disease beyond 1 year after revascularization and no stent thrombosis	Use oral anticoagulant monotherapy rather than adding single antiplatelet therapy.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	Document competing coronary or thrombotic indications.

Rhythm Control

Use rhythm control deliberately and refer for ablation when it changes outcomes

Rhythm control is increasingly early and outcome-oriented, particularly in HFrEF.

The current U.S. guideline framework emphasizes early and continued management aimed at maintaining sinus rhythm and minimizing AF burden.jaccjacc2023 Atrial Fibrillation Guideline-at-a-Glance Shared decision-making should compare rate and rhythm strategies, incorporating symptom burden, comorbidity, drug risks, procedural candidacy, and patient goals.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

Catheter ablation is useful for symptomatic AF when antiarrhythmic drugs are ineffective, contraindicated, not tolerated, or not preferred and rhythm control remains desired. In symptomatic or clinically significant atrial flutter, catheter ablation is also useful for symptom improvement.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Pulmonary vein isolation is the recommended primary lesion set for AF ablation unless a different specific trigger is identified.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

In selected patients, generally younger individuals with few comorbidities and symptomatic paroxysmal AF who desire rhythm control, catheter ablation is a Class 1 first-line option to improve symptoms and reduce progression to persistent AF.jaccjacc2023 Atrial Fibrillation Guideline-at-a-Glance
Perform AF ablation on uninterrupted therapeutic warfarin with INR 2.0-3.0, or continuous/minimally interrupted DOAC therapy.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Dronedarone is indicated to reduce AF hospitalization in patients in sinus rhythm with a history of paroxysmal or persistent AF, but is contraindicated in permanent AF and in recent decompensated or NYHA class IV heart failure.dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009

Rhythm-control drug safety issues with immediate clinical consequences.dailymed nlm nih+1dailymed nlm nihThese highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009 jacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Drug or strategy	Do not use when	Operational requirement
Flecainide or propafenone	Previous MI or significant structural heart disease, including HFrEF with LVEF ≤40%.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	Avoid because of worsening HF, proarrhythmia, and increased mortality risk.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Dronedarone	Permanent AF; NYHA class IV HF; or symptomatic HF with recent decompensation requiring hospitalization.dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009	Check rhythm at least every 3 months; discontinue or cardiovert if AF recurs.dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009
Dofetilide	Outpatient initiation or dose escalation.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association	Initiate or increase dose with at least 3 days of inpatient continuous ECG monitoring, creatinine-clearance calculation, and resuscitation capability.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
AF ablation	When oral anticoagulation cannot safely be managed without a compelling individualized plan.	Use uninterrupted warfarin or continuous/minimally interrupted DOAC therapy.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

AF with HFrEF

In new HFrEF with AF, suspect arrhythmia-induced cardiomyopathy and pursue an early, aggressive rhythm-control approach.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association In appropriate patients with AF and HFrEF who are receiving guideline-directed therapy and have reasonable expected procedural benefit, catheter ablation improves symptoms, quality of life, ventricular function, and cardiovascular outcomes.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

In CASTLE-AF, catheter ablation reduced the composite of death or heart-failure hospitalization versus medical therapy in a selected HFrEF population; the review reports composite event rates of 28.5% versus 44.6%.BMJBMJUpdate on management of atrial fibrillation in heart failure: a focus on ablation | Heart Applicability depends on patient selection, AF burden, ventricular function, comorbidity, and procedural access.BMJBMJUpdate on management of atrial fibrillation in heart failure: a focus on ablation | Heart

Longitudinal Care

Treat AF as a progressive cardiometabolic disease

Prevent recurrence, progression, and complications while monitoring treatment safety.

Lifestyle and risk-factor modification is a central component of AF management. For BMI >27 kg/m², target at least 10% weight loss; recommend moderate-to-vigorous activity totaling 210 minutes weekly; provide tobacco-cessation treatment; counsel alcohol minimization or elimination for patients pursuing rhythm control; and optimize blood pressure in patients with hypertension.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

AF discovered during acute medical illness or surgery should not be dismissed as transient. Patients should be counseled about recurrence risk after the acute trigger resolves; cited recurrence estimates are 42% to 68% after acute medical illness and 39% after surgery over five years.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

For dronedarone, obtain rhythm surveillance at least every 3 months; discontinue the drug or cardiovert if AF is detected.dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009
Monitor potassium and magnesium when using potassium-depleting diuretics with dronedarone, and monitor renal function periodically. A small early creatinine rise may reflect inhibited tubular secretion, but marked creatinine increase or renal failure can occur, often with heart failure or hypovolemia.dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009
Evaluate new dyspnea or nonproductive cough for possible dronedarone pulmonary toxicity; discontinue if confirmed. Evaluate suspected hepatic injury promptly and do not restart without another explanation.dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009

Secondary prevention targets in established AF.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Risk domain	Action	Target or trigger
Overweight or obesity	Offer structured weight-loss management.	BMI >27 kg/m²; ideal target ≥10% weight loss.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Physical inactivity	Prescribe moderate-to-vigorous exercise when clinically appropriate.	210 minutes weekly.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Tobacco	Provide cessation counseling and guideline-directed cessation treatment.	Any cigarette smoking history in AF.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Alcohol	Counsel minimization or elimination when rhythm control is sought.	Relevant alcohol use in AF.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association
Hypertension	Optimize blood-pressure treatment.	Confirmed hypertension with AF.jaccjacc2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association